Loading clinical trials...
Loading clinical trials...
A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)
Conditions
Interventions
Vedolizumab
Placebo
Locations
18
United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Texas Digestive Disease Consultants
Southlake, Texas, United States
Virginia Mason Medical Center
Seattle, Washington, United States
University of Calgary
Calgary, Alberta, Canada
GIRI (GI Research Institute)
Vancouver, British Columbia, Canada
CHRU de Lille - Hopital Claude Huriez
Lille, France
Start Date
August 10, 2016
Primary Completion Date
September 4, 2018
Completion Date
November 14, 2018
Last Updated
November 19, 2019
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07377188
NCT07385131
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions